生物合成技术

Search documents
欧康医药(833230) - 投资者关系活动记录表
2025-04-30 12:15
Group 1: Investor Relations Activities - The company held a performance briefing for the 2024 annual report on April 29, 2025, via online communication [4] - Participants included the chairman, general manager, board secretary, financial officer, and sponsor representative [4] Group 2: Market Expansion and Product Certification - The company has obtained the EU export certification for its products, which requires compliance with the European Pharmacopoeia (CEP) and on-site inspections [5] - The company aims to enhance its competitiveness in the EU market by improving production quality and collaborating with EU clients [5] Group 3: Revenue Composition and Market Share - The company's revenue is primarily derived from pharmaceutical raw materials, food additives, cosmetics, and health products [6] - The European market accounts for approximately 40% of exports, while the US, Japan, Australia, and Canada account for about 60% [6] - The NHDC product has captured over 27% of the company's main business revenue in the domestic food additive market [6] Group 4: Growth Drivers and Strategic Focus - Future growth in the plant extract industry is driven by increasing consumer health awareness and advancements in extraction technology [8] - The company plans to deepen its focus on both domestic and international markets, particularly in food additives and pharmaceutical raw materials [9] Group 5: Financial Performance and Profit Margins - The company's revenue increased by 27.78% year-on-year in 2024, attributed to the successful implementation of its strategic plan [7] - The overall gross margin for products increased in 2024, but is expected to decline in 2025 due to rising costs and market competition [10] Group 6: Production and R&D Updates - The company is currently optimizing production processes and has completed 11 R&D projects in 2024 [15] - The new production lines are expected to be fully operational by mid-2025, which will enhance production capacity [14] Group 7: Market Trends and Future Outlook - The company anticipates a gradual recovery in gross margins as production lines stabilize and international trade conditions improve [12][13] - The market for Vitamin P products is expected to grow significantly due to rising health consciousness and expanding application areas [17]
90%的护肤品中都添加了它,玻尿酸真的过气了吗?
36氪未来消费· 2025-04-21 11:20
真正优秀的成分,总会随着时间焕发新的生命力。 在护肤领域,透明质酸( HA),也就是我们熟知的玻尿酸,堪称初代 "顶流巨星"。从保湿到抗皱,从修复到紧致,它的功效几乎覆盖了消费者对护肤 品的所有期待。然而,随着胜肽、烟酰胺等新兴成分的涌现,一时间,质疑声四起:曾经风靡护肤界的玻尿酸,如今是否还能保持它的优势? 这种断层式领先表明,无论市场如何变化,透明质酸依然是品牌配方中的核心选择。 为什么透明质酸能够保持这样的地位?答案很简单 ——它不仅是一种经典成分,更是一种经过时间验证、安全可靠且功效显著的护肤原料。 透明质酸 的抗皱紧致 地位坚如磐石 数据不会撒谎。 根据中国香妆和用户说联合发布的《 2025原料成分趋势洞察榜单》,透明质酸稳坐"抗皱紧致"成分应用热度榜首。在2025年1-2月备 案的护肤品中,含有透明质酸的产品数量高达10562个,是第二名烟酰胺(5504个)的近两倍。 早期的透明质酸提取工艺复杂且成本高昂。 1949 年,Boas 从鸡冠中分离出透明质酸。提取 1g 透明质酸需要 200 公斤鸡冠(约 2 万只鸡),导致生 产成本极高,每公斤售价高达10万美元,被誉为"液体黄金"。 从 "液体黄金 ...